Effect of Metformin (MET) in Protection against Oxidative Stress and Pancreatic Damage Using an Animal Model
Abstract
Aim: The present study investigated the effects of metformin (MET) in protection against oxidative stress and pancreatic damage using an animal model, to assess the effect of metformin on oxidative stress in vivo and in vitro. Introduction: Diabetes mellitus is a worldwide health problem that has a deleterious impact on life expectancy and quality. People with diabetes have a higher oxidation state, which is detrimental to homeostasis. Numerous tissues have demonstrated the anti-oxidant qualities of metformin. An oral medication for diabetes called metformin aids in blood sugar regulation. Methods: This study investigated the effect of metformin on total antioxidant markers in the serum and pancreatic tissue of Alloxan-induced diabetic rats. Diabetic rats were randomised into five groups for treatment and received metformin (100,200,300 mg/kg) orally once daily for four weeks. The antioxidant potential of evaluated total antioxidant status (TAOS) in vivo and through DPPH (1,1-diphenyl-2-picryl-hydrazyl) scavenging assay at 517 nm in vitro. Results: A Considerable drop in elevated blood glucose level was observed in the alloxan-induced diabetic. At a dose of 100,200,300mg/kg demonstrated increase significantly improvement rate percentage in (M100, M200, M300) were (40.701 %),(48.063%) and (48.101%) respectively after end of treatment compared to diabetic group that decrease (-243.340%), TAOS were significantly increased in treated group than diabetic group" p= 0.000* ".The…
How strong is the evidence?
Evidence Hub reads this as a book / chapter, done in animal, not in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.